Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T12:31:36.277Z Has data issue: false hasContentIssue false
  • English
  • Français

The different interpretations of the mechanism of action of antimitotics and the actual treatment of malignant hemopathies

Published online by Cambridge University Press:  01 August 2014

A. Baserga
A. Baserga*
Affiliation:
Istituto di Clinica Medica dell'Università di Ferrara

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Antimitotic drugs essentially induce a direct inhibition on the malignant cellular proliferation. Secondary mechanisms should even be considered: i.e. neoplastic clonal disadvantage, indirect antivitaminic mechanism for the intestinal atrophy caused by antimitotic drugs, endocrine failance due to the antimitotic drugs damages in the endocrine glands (pharmacological « hypophysectomy » and « castraction ») etc.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 279 - 282
Copyright
Copyright © The International Society for Twin Studies 1968

References

Bibliographie

Baserga, A. (1961). Etiopatogenesi delle leucemie. Riforma Med., 75: 13.Google Scholar
Baserga, A., Mariuzzi, G. M. (1954). Inibizione con antimitotici di effetti di tropine ipofisarie. Il Farmaco, 3: 548.Google Scholar
Baserga, A., Morsiani, G. M. (1958). Le enteropatie arigenerative. Rassegna Med., 35: 208.Google Scholar
Baserga, A., Castoldi, G. I. (1963). Antineoplastische Chemotherapie und endokrine Drüsen. III Internat. Congr. Chemother., Stuttgart Thieme, 1078.Google Scholar